Albumin-binding interactions of sodium valproate.
In vitro equilibrium dialysis experiments show that salicylate and phenylbutazone displace valproate from its binding sites on human serum albumin at therapeutic concentrations, whereas warfarin and carbamazepin do not.
D001665:Binding Sites; D002220:Carbamazepine / Q000378:metabolism; D004347:Drug Interactions; D006801:Humans; D066298:In Vitro Techniques; D010653:Phenylbutazone / Q000378:metabolism; D011485:Protein Binding; D012459:Salicylates / Q000378:metabolism; D012709:Serum Albumin / Q000378:metabolism*; D014635:Valproic Acid / Q000378:metabolism*; D014859:Warfarin / Q000378:metabolism
D012459:Salicylates; D012709:Serum Albumin; D002220:Carbamazepine; D014859:Warfarin; D014635:Valproic Acid; D010653:Phenylbutazone